{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T15:32:47Z","timestamp":1793892767659,"version":"4.8.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,11,20]]},"DOI":"10.1038\/s41416-026-03602-y","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T18:06:02Z","timestamp":1788026762000},"page":"1657-1665","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prospective validation of a urine-based proteomics test for predicting clinically significant prostate cancer in biopsy-na\u00efve patients"],"prefix":"10.1038","volume":"135","author":[{"given":"Ana C.","family":"Morillo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirubel Nigusu","family":"Jobre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Lendinez Cano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Blanca-Pedregosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Lopez Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Parada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Heidegger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoran","family":"Culig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Lopez-Beltran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Carrasco-Valiente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Mischak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael A.","family":"Medina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan P.","family":"Campos Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Frantzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8753-3306","authenticated-orcid":false,"given":"Enrique","family":"G\u00f3mez G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,29]]},"reference":[{"key":"3602_CR1","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","volume":"86","author":"P Cornford","year":"2024","unstructured":"Cornford P, Van Den Bergh RCN, Briers E, Van Den Broeck T, Brunckhorst O, Darraugh J, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer\u20142024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2024;86:148\u201363. https:\/\/doi.org\/10.1016\/j.eururo.2024.03.027.","journal-title":"Eur Urol"},{"key":"3602_CR2","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.eururo.2019.08.005","volume":"77","author":"MB Culp","year":"2020","unstructured":"Culp MB, Soerjomataram I, Efstathiou JA, Bray F, Jemal A. Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates. Eur Urol. 2020;77:38\u201352. https:\/\/doi.org\/10.1016\/j.eururo.2019.08.005.","journal-title":"Eur Urol"},{"key":"3602_CR3","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1007\/s00345-022-04077-1","volume":"40","author":"M Frantzi","year":"2022","unstructured":"Frantzi M, Heidegger I, Roesch MC, Gomez-Gomez E, Steiner E, Vlahou A, et al. Validation of diagnostic nomograms based on CE-MS urinary biomarkers to detect clinically significant prostate cancer. World J Urol. 2022;40:2195\u2013203. https:\/\/doi.org\/10.1007\/s00345-022-04077-1.","journal-title":"World J Urol"},{"key":"3602_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.euros.2022.06.006","volume":"43","author":"B Isra\u00ebl","year":"2022","unstructured":"Isra\u00ebl B, Hannink G, Barentsz JO, Van Der Leest MMG. Implications of the European Association of Urology Recommended Risk Assessment Algorithm for Early Prostate Cancer Detection. Eur Urol Open Sci. 2022;43:1\u20134. https:\/\/doi.org\/10.1016\/j.euros.2022.06.006.","journal-title":"Eur Urol Open Sci"},{"key":"3602_CR5","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1001\/jama.2018.3712","volume":"319","author":"JJ Fenton","year":"2018","unstructured":"Fenton JJ, Weyrich MS, Durbin S, Liu Y, Bang H, Melnikow J. Prostate-specific antigen-based screening for prostate cancer: evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2018;319:1914\u201331. https:\/\/doi.org\/10.1001\/jama.2018.3712.","journal-title":"JAMA"},{"key":"3602_CR6","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1370\/afm.2205","volume":"16","author":"L Naji","year":"2018","unstructured":"Naji L, Randhawa H, Sohani Z, Dennis B, Lautenbach D, Kavanagh O, et al. Digital rectal examination for prostate cancer screening in primary care: a systematic review and meta-analysis. Ann Fam Med. 2018;16:149\u201354. https:\/\/doi.org\/10.1370\/afm.2205.","journal-title":"Ann Fam Med"},{"key":"3602_CR7","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.eururo.2019.02.033","volume":"76","author":"B Turkbey","year":"2019","unstructured":"Turkbey B, Rosenkrantz AB, Haider MA, Padhani AR, Villeirs G, Macura KJ, et al. Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. Eur Urol. 2019;76:340\u201351. https:\/\/doi.org\/10.1016\/j.eururo.2019.02.033.","journal-title":"Eur Urol"},{"key":"3602_CR8","doi-asserted-by":"publisher","unstructured":"Drost FJH, Osses DF, Nieboer D, Steyerberg EW, Bangma CH, Roobol MJ, et al. Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer. Cochrane Urology Group, ed. Cochrane Database Syst Rev. 2019;2019. https:\/\/doi.org\/10.1002\/14651858.CD012663.pub2","DOI":"10.1002\/14651858.CD012663.pub2"},{"key":"3602_CR9","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.231130","volume":"309","author":"F Giganti","year":"2023","unstructured":"Giganti F, Ng A, Asif A, Chan VWS, Rossiter M, Nathan A, et al. Global variation in magnetic resonance imaging quality of the prostate. Radiology. 2023;309:e231130. https:\/\/doi.org\/10.1148\/radiol.231130.","journal-title":"Radiology"},{"key":"3602_CR10","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.euf.2017.11.010","volume":"5","author":"GA Sonn","year":"2019","unstructured":"Sonn GA, Fan RE, Ghanouni P, Wang NN, Brooks JD, Loening AM, et al. Prostate magnetic resonance imaging interpretation varies substantially across radiologists. Eur Urol Focus. 2019;5:592\u20139. https:\/\/doi.org\/10.1016\/j.euf.2017.11.010.","journal-title":"Eur Urol Focus"},{"key":"3602_CR11","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1148\/radiol.2020190646","volume":"296","author":"AC Westphalen","year":"2020","unstructured":"Westphalen AC, McCulloch CE, Anaokar JM, Arora S, Barashi NS, Barentsz JO, et al. Variability of the positive predictive value of PI-RADS for prostate MRI across 26 centers: experience of the Society of Abdominal Radiology Prostate Cancer Disease-focused Panel. Radiology. 2020;296:76\u201384. https:\/\/doi.org\/10.1148\/radiol.2020190646.","journal-title":"Radiology"},{"key":"3602_CR12","doi-asserted-by":"publisher","DOI":"10.1177\/17562872221103988","volume":"14","author":"MW Farha","year":"2022","unstructured":"Farha MW, Salami SS. Biomarkers for prostate cancer detection and risk stratification. Ther Adv Urol. 2022;14:17562872221103988. https:\/\/doi.org\/10.1177\/17562872221103988.","journal-title":"Ther Adv Urol"},{"key":"3602_CR13","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1038\/s41416-019-0472-z","volume":"120","author":"M Frantzi","year":"2019","unstructured":"Frantzi M, Gomez Gomez E, Blanca Pedregosa A, Valero Rosa J, Latosinska A, Culig Z, et al. CE-MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer. Br J Cancer. 2019;120:1120\u20138. https:\/\/doi.org\/10.1038\/s41416-019-0472-z.","journal-title":"Br J Cancer"},{"key":"3602_CR14","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/s41416-022-02046-4","volume":"128","author":"DF Hayes","year":"2023","unstructured":"Hayes DF, Sauerbrei W, McShane LM. REMARK guidelines for tumour biomarker study reporting: a remarkable history. Br J Cancer. 2023;128:443\u20135. https:\/\/doi.org\/10.1038\/s41416-022-02046-4.","journal-title":"Br J Cancer"},{"key":"3602_CR15","doi-asserted-by":"publisher","first-page":"46ps42","DOI":"10.1126\/scitranslmed.3001249","volume":"2","author":"H Mischak","year":"2010","unstructured":"Mischak H, Allmaier G, Apweiler R, Attwood T, Baumann M, Benigni A, et al. Recommendations for biomarker identification and qualification in clinical proteomics. Sci Transl Med. 2010;2:46ps42. https:\/\/doi.org\/10.1126\/scitranslmed.3001249.","journal-title":"Sci Transl Med"},{"key":"3602_CR16","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.juro.2018.05.016","volume":"200","author":"A Aminsharifi","year":"2018","unstructured":"Aminsharifi A, Howard L, Wu Y, De Hoedt A, Bailey C, Freedland SJ, et al. Prostate specific antigen density as a predictor of clinically significant prostate cancer when the prostate specific antigen is in the diagnostic gray zone: defining the optimum cutoff point stratified by race and Body Mass Index. J Urol. 2018;200:758\u201366. https:\/\/doi.org\/10.1016\/j.juro.2018.05.016.","journal-title":"J Urol"},{"key":"3602_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-62015-w","volume":"10","author":"J Liu","year":"2020","unstructured":"Liu J, Dong B, Qu W, Wang J, Xu Y, Yu S, et al. Using clinical parameters to predict prostate cancer and reduce the unnecessary biopsy among patients with PSA in the gray zone. Sci Rep. 2020;10:5157. https:\/\/doi.org\/10.1038\/s41598-020-62015-w.","journal-title":"Sci Rep"},{"key":"3602_CR18","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1097\/PAS.0000000000001497","volume":"44","author":"GJLH van Leenders","year":"2020","unstructured":"van Leenders GJLH, van der Kwast TH, Grignon DJ, Evans AJ, Kristiansen G, Kweldam CF, et al. The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma. Am J Surg Pathol. 2020;44:e87\u2013e99. https:\/\/doi.org\/10.1097\/PAS.0000000000001497.","journal-title":"Am J Surg Pathol"},{"key":"3602_CR19","doi-asserted-by":"publisher","unstructured":"Frantzi M, Morillo AC, Lend\u00ednez G, Blanca A, L\u00f3pez Ruiz D, Parada J, et al. Validation of a urine-based proteomics test to predict clinically significant prostate cancer: complementing mpMRI Pathway. Pathobiol J Immunopathol Mol Cell Biol. Published online November, 2024:1-10. https:\/\/doi.org\/10.1159\/000542465","DOI":"10.1159\/000542465"},{"key":"3602_CR20","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.clinbiochem.2012.09.025","volume":"46","author":"H Mischak","year":"2013","unstructured":"Mischak H, Vlahou A, Ioannidis JPA. Technical aspects and inter-laboratory variability in native peptide profiling: the CE-MS experience. Clin Biochem. 2013;46:432\u201343. https:\/\/doi.org\/10.1016\/j.clinbiochem.2012.09.025.","journal-title":"Clin Biochem"},{"key":"3602_CR21","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1002\/elps.201900091","volume":"40","author":"A Latosinska","year":"2019","unstructured":"Latosinska A, Siwy J, Mischak H, Frantzi M. Peptidomics and proteomics based on CE-MS as a robust tool in clinical application: The past, the present, and the future. Electrophoresis. 2019;40:2294\u2013308. https:\/\/doi.org\/10.1002\/elps.201900091.","journal-title":"Electrophoresis"},{"key":"3602_CR22","doi-asserted-by":"publisher","first-page":"7260","DOI":"10.3390\/molecules26237260","volume":"26","author":"E Mavrogeorgis","year":"2021","unstructured":"Mavrogeorgis E, Mischak H, Latosinska A, Siwy J, Jankowski V, Jankowski J. Reproducibility evaluation of urinary peptide detection using CE-MS. Molecules. 2021;26:7260. https:\/\/doi.org\/10.3390\/molecules26237260.","journal-title":"Molecules"},{"key":"3602_CR23","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jprot.2013.12.010","volume":"98","author":"M Frantzi","year":"2014","unstructured":"Frantzi M, Metzger J, Banks RE, Husi H, Klein J, Dakna M, et al. Discovery and validation of urinary biomarkers for detection of renal cell carcinoma. J Proteom. 2014;98:44\u201358. https:\/\/doi.org\/10.1016\/j.jprot.2013.12.010.","journal-title":"J Proteom"},{"key":"3602_CR24","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1002\/prca.201000155","volume":"5","author":"J Siwy","year":"2011","unstructured":"Siwy J, Mullen W, Golovko I, Franke J, Z\u00fcrbig P. Human urinary peptide database for multiple disease biomarker discovery. Proteom Clin Appl. 2011;5:367\u201374. https:\/\/doi.org\/10.1002\/prca.201000155.","journal-title":"Proteom Clin Appl"},{"key":"3602_CR25","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1016\/j.spinee.2021.02.024","volume":"21","author":"AJ Vickers","year":"2021","unstructured":"Vickers AJ, Holland F. Decision curve analysis to evaluate the clinical benefit of prediction models. Spine J J North Am Spine Soc. 2021;21:1643\u20138. https:\/\/doi.org\/10.1016\/j.spinee.2021.02.024.","journal-title":"Spine J J North Am Spine Soc"},{"key":"3602_CR26","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.euros.2024.12.007","volume":"71","author":"M Arvendell","year":"2025","unstructured":"Arvendell M, Phillips L, Delilovic S, Enelius MB, Olsson K, Bolejko A, et al. Men\u2019s attitudes towards participation in organised prostate cancer testing: an abductive thematic analysis. Eur Urol Open Sci. 2025;71:156\u201364. https:\/\/doi.org\/10.1016\/j.euros.2024.12.007.","journal-title":"Eur Urol Open Sci"},{"key":"3602_CR27","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1056\/NEJMoa2503223","volume":"393","author":"Roobol","year":"2025","unstructured":"Roobol, De Vos II MJ, M\u00e5nsson M, Godtman RA, Talala KM, Den Hond E, et al. European Study of Prostate Cancer Screening \u2014 23-Year Follow-up. N Engl J Med. 2025;393:1669\u201380. https:\/\/doi.org\/10.1056\/NEJMoa2503223.","journal-title":"N Engl J Med"},{"key":"3602_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-57337-y","volume":"14","author":"J Wen","year":"2024","unstructured":"Wen J, Liu W, Shen X, Hu W. PI-RADS v2.1 and PSAD for the prediction of clinically significant prostate cancer among patients with PSA levels of 4\u201310 ng\/ml. Sci Rep. 2024;14:6570. https:\/\/doi.org\/10.1038\/s41598-024-57337-y.","journal-title":"Sci Rep"},{"key":"3602_CR29","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/pros.24182","volume":"81","author":"G Lend\u00ednez-Cano","year":"2021","unstructured":"Lend\u00ednez-Cano G, Ojeda-Claro AV, G\u00f3mez-G\u00f3mez E, Morales Jimenez P, Flores Martin J, Dominguez JF, et al. Prospective study of diagnostic accuracy in the detection of high-grade prostate cancer in biopsy-na\u00efve patients with clinical suspicion of prostate cancer who underwent the Select MDx test. Prostate. 2021;81:857\u201365. https:\/\/doi.org\/10.1002\/pros.24182.","journal-title":"Prostate"},{"key":"3602_CR30","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1002\/pros.24838","volume":"85","author":"M Oderda","year":"2025","unstructured":"Oderda M, Marquis A, Bertero L, Calleris G, Faletti R, Gatti M, et al. Histopathologic features and transcriptomic signatures do not solve the issue of magnetic resonance imaging-invisible prostate cancers: a matched-pair analysis. Prostate. 2025;85:374\u201384. https:\/\/doi.org\/10.1002\/pros.24838.","journal-title":"Prostate"},{"key":"3602_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.euo.2018.08.005","volume":"2","author":"MA Parry","year":"2019","unstructured":"Parry MA, Srivastava S, Ali A, Cannistraci A, Antonello J, Barros-Silva JD, et al. Genomic evaluation of multiparametric magnetic resonance imaging-visible and -nonvisible lesions in clinically localised prostate cancer. Eur Urol Oncol. 2019;2:1\u201311. https:\/\/doi.org\/10.1016\/j.euo.2018.08.005.","journal-title":"Eur Urol Oncol"},{"key":"3602_CR32","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.euf.2022.08.013","volume":"8","author":"L Groen","year":"2022","unstructured":"Groen L, Schalken J. Liquid biopsy for prostate and bladder cancer: progress and pitfalls. Eur Urol Focus. 2022;8:904\u20136. https:\/\/doi.org\/10.1016\/j.euf.2022.08.013.","journal-title":"Eur Urol Focus"},{"key":"3602_CR33","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.euo.2024.05.014","volume":"8","author":"I Heidegger","year":"2025","unstructured":"Heidegger I, Frantzi M, Salcher S, Tymoszuk P, Martowicz A, Gomez-Gomez E, et al. Prediction of clinically significant prostate cancer by a specific collagen-related transcriptome, proteome, and urinome signature. Eur Urol Oncol. 2025;8:652\u201362. https:\/\/doi.org\/10.1016\/j.euo.2024.05.014.","journal-title":"Eur Urol Oncol"},{"key":"3602_CR34","doi-asserted-by":"publisher","unstructured":"Frantzi M, Tymoszuk P, Salcher S, G\u00f3mez-G\u00f3mez E, Morillo AC, Melchior F, et al. Prediction of prostate cancer biochemical recurrence after radical prostatectomy by collagen models using multiomic profiles. Eur Urol Oncol. Published online April, 2025:S2588-9311:00094-X. https:\/\/doi.org\/10.1016\/j.euo.2025.03.016","DOI":"10.1016\/j.euo.2025.03.016"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03602-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03602-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03602-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T14:53:15Z","timestamp":1793890395000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03602-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,29]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,11,20]]}},"alternative-id":["3602"],"URL":"https:\/\/doi.org\/10.1038\/s41416-026-03602-y","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,29]]},"assertion":[{"value":"13 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Prof. Harald Mischak has ownership stakes in Mosaiques Diagnostics GmbH. Dr. Maria Frantzi and Dr. Kirubel Nigusu Jobre are employed by Mosaiques Diagnostics. The other authors have no conflict of interest to declare.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The research protocol for this study was evaluated and sanctioned by the \u201cReina Sofia Hospital Research Ethics Committee,\u201d with Approval No. [(no. 340, ref 5454), PI22\/01769]. All study procedures were conducted in accordance with the applicable ethical guidelines, regulations, and institutional requirements. Informed consent in written form was acquired from all participants.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Ethics"}}]}}